Mineralys Therapeutics (MLYS) Other Non Operating Income (2022 - 2026)

Mineralys Therapeutics has reported Other Non Operating Income for 5 years, with the latest figure at $5000.0 in Q1 2026.

• Quarterly Other Non Operating Income rose 266.67% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8000.0 (up 700.0% YoY) and the FY2024 annual result came in at $5000.0, up 66.67% from the prior year.
• Other Non Operating Income grew to $5000.0 in Q1 2026 per MLYS's latest filing, from $1000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $12000.0 in Q4 2024 and troughed at -$10000.0 in Q3 2024.
• A 5-year average of $1307.7 and a median of $1000.0 in 2023 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Other Non Operating Income surged 1100.0% in 2024, then slumped 400.0% in 2025.
• Over 5 years, Other Non Operating Income stood at $4000.0 in 2022, then slumped by 75.0% to $1000.0 in 2023, then soared by 1100.0% to $12000.0 in 2024, then sank by 91.67% to $1000.0 in 2025, then soared by 400.0% to $5000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $5000.0, $1000.0, and $4000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.